PAR General discussion, page-222

Mozz an interesting point about the narrow label.
Why not set in place a two stage approach, narrow then full.
Too late now i suppose, the picky FDA don't like change, but it might have been a good idea after the first go around 10 months ago.
But why didn't they investigate that? Because they don't think outside the square so to speak.

Re your point 2: "and the program has had a 12 month extension study built in" -- ought management not be accountable for that miss up front?
3) same question
4) & 5) PAR mgmt underestimated the schedule and scope just like pre Nov 2019.

I remain unconvinced that management are especially competent in project management or that the Bod are especially competent in capital management.

They need to be pressed on accountability.